Why Invest in Theralase Technologies?

Patented Therapeutic Medical Laser Technology

• Proven clinical technology, rated #1 in the industry (TLC-1000)
• Commercial therapeutic laser business and brand developed over last 17 years
• Approved by the FDA, CE and Health Canada
• Listed on the Toronto Venture Stock Exchange: TLT
• No debt
• Positive cash flow / great growth potential
• PDC cancer destruction in animals helps pay for human trials
• Patented technology destroys E. coli and Listeria bacteria  
• Competitive technical advantage (Cellular pathways: iNOS, ATP, Na+ / K+)
• Large addressable US market ($ billions)
• Future technology (Patented biofeedback technology and patented PDC cancer destruction)
• Light sensitive, patented PDCs have fully destroyed Listeria and E. coli bacteria  
• Opportunity for growth (revenue, profit)
• IP protection (multiple issued patents)
• Experienced management team (20+ years)
• Clear vision and execution strategy

Business Objectives (2011 - 2012)

• Expansion into the US market, hire experienced medical equipment sales professionals
• Seminar Series (major US cities)
• Speaking Engagements at Trade Shows
• Active Educational Webinar program
• Customer Referral Program
• Partnerships with Medical and Chiropractic Colleges

Launch of TLC-2000 Biofeedback Therapeutic Laser employing a recurring revenue model
Commence TLC-3000 and PDC small animal in vivo pre-clinical trial for cancer destruction

A Sound Investment in Medical Treatment Technology

An investment in Theralase is an investment in the cutting edge of advanced medical treatment technology. A solid reputation built on advanced research and development, an experienced management team and proven patented technology make Theralase an investment with unlimited potential.

Company Profile

Theralase Technologies Inc. designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound care. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria and viruses. Theralase lasers are FDA, Health Canada and CSA/UL approved, and have international ISO 13485 certification.

Theralase's strategy includes three parts: 1) production, marketing and distribution of the Theralase super-pulsed laser for sale to health-care practitioners (focusing on the treatment of chronic pain, sports injuries and wounds); 2) commercialization of (i) patented cancer treatment through progressive research, clinical trials and advancement of new technology in the direct destruction of cancers and (ii) destruction of bacteria and viruses through research utilizing patented, light-sensitive Photo Dynamic Compounds and 3) Partner with universities, colleges, government agencies and other organizations for research and development opportunities.

For more information please call 1-866-843-5273 or visit www.theralase.com


This posting does not constitute an offer of any securities for sale.This posting contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein.